{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:32Z","timestamp":1792008092517,"version":"4.4.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["555592275"],"award-info":[{"award-number":["555592275"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.kint.2026.01.032","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:49:14Z","timestamp":1772207354000},"page":"869-882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tiny warriors, big impact: targeted immunotherapy in kidney diseases"],"prefix":"10.1016","volume":"109","author":[{"given":"Johanna T.","family":"Kurzhagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Laqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-5135","authenticated-orcid":false,"given":"Ricardo","family":"Grieshaber-Bouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Rabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8414-1470","authenticated-orcid":false,"given":"Mario","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.01.032_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2026.01.032_bib2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.01.032_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2026.01.032_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.01.032_bib5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.032_bib6","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.01.032_bib7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.01.032_bib8","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.3390\/jcm10173773","article-title":"Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives","volume":"10","author":"Treppo","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.kint.2026.01.032_bib9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"Dorner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.kint.2026.01.032_bib10","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.032_bib11","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib12","article-title":"Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis","volume":"11","author":"Mo","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2026.01.032_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib14","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.kint.2026.01.032_bib126","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2026.01.032_bib16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.01.032_bib17","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.01.032_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.01.032_bib19","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.01.032_bib20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H","article-title":"Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus","volume":"41","author":"Herrmann","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.01.032_bib21","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2026.01.032_bib23","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.kint.2026.01.032_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001436","article-title":"Obinutuzumab effectively depletes key B-cell subsets in blood and tissue in end-stage renal disease patients","volume":"9","author":"Looney","year":"2023","journal-title":"Transplant Direct"},{"key":"10.1016\/j.kint.2026.01.032_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.kint.2026.01.032_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2026.01.032_bib27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.humpath.2005.08.005","article-title":"BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders","volume":"36","author":"Rodig","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1016\/j.kint.2026.01.032_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1235937","article-title":"BAFF system expression in double negative 2, activated naive and activated memory B cells in systemic lupus erythematosus","volume":"14","author":"Alvarez Gomez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.01.032_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.kint.2026.01.032_bib34","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kint.2026.01.032_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kint.2026.01.032_bib37","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib38","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.01.032_bib41","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.01.032_bib42","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.kint.2026.01.032_bib43","article-title":"An open-label, multicenter, phase 1\/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T cell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: preliminary results [abstract]","volume":"75","author":"Cort\u00e9s Hern\u00e1ndez","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.01.032_bib44","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.kint.2026.01.032_bib45","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1182\/blood-2023-186669","article-title":"CD19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus\u2014safety and preliminary efficacy data from a phase I clinical study","volume":"142","author":"Feng","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.032_bib127","unstructured":"Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases (CATARSIS). ClinicalTrials.gov Identifier: NCT06685042. Updated April 11, 2025. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06685042"},{"key":"10.1016\/j.kint.2026.01.032_bib128","unstructured":"Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases. ClinicalTrials.gov Identifier: NCT06548607. Updated March 6, 2026. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06548607"},{"key":"10.1016\/j.kint.2026.01.032_bib129","unstructured":"Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases. ClinicalTrials.gov Identifier: NCT06316076. Updated March 18, 2024. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06316076"},{"key":"10.1016\/j.kint.2026.01.032_bib130","unstructured":"CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 (CARTIMMUNE). ClinicalTrials.gov Identifier: NCT06152172. Updated February 18, 2026. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06152172"},{"key":"10.1016\/j.kint.2026.01.032_bib131","unstructured":"IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients. ClinicalTrials.gov Identifier: NCT06690359. Updated November 26, 2026. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06690359"},{"key":"10.1016\/j.kint.2026.01.032_bib46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41392-024-01998-8","article-title":"Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future","volume":"9","author":"Mougiakakos","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.kint.2026.01.032_bib47","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1016\/j.cell.2024.07.056","article-title":"Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases","volume":"187","author":"Baker","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.kint.2026.01.032_bib48","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2022016204","article-title":"Genome-edited allogeneic donor \"universal\" chimeric antigen receptor T cells","volume":"141","author":"Qasim","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.032_bib49","article-title":"CAR NK cell therapy for T follicular helper cells","volume":"1","author":"King","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.kint.2026.01.032_bib50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.kint.2026.01.032_bib51","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.kint.2026.01.032_bib52","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.01.032_bib53","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1182\/blood.V126.23.4426.4426","article-title":"Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy","volume":"126","author":"Bot","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.032_bib54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1191\/096120399678840954","article-title":"Successful treatment of lupus with fludarabine","volume":"8","author":"Viallard","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2026.01.032_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion\u2014an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.01.032_bib57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.kint.2026.01.032_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.kint.2026.01.032_bib59","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.3390\/jcm10215190","article-title":"Cytokine release syndrome in the immunotherapy of hematological malignancies: the biology behind and possible clinical consequences","volume":"10","author":"Tvedt","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.kint.2026.01.032_bib60","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/COC.0000000000001124","article-title":"Optimization strategies in CAR T-cell therapy: a comprehensive evaluation of cytopenia, HLH\/MAS, and other adverse events","volume":"47","author":"Qureshi","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.032_bib61","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2026.01.032_bib62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2026.01.032_bib63","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"Muller","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.032_bib64","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146743","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2026.01.032_bib65","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.kint.2026.01.032_bib66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/ar4232","article-title":"Natural killer cells in human autoimmune disorders","volume":"15","author":"Fogel","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2026.01.032_bib67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.kint.2026.01.032_bib68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ndt\/gfae165","article-title":"CAAR NK and T cells to eliminate autoreactive lymphocytes in autoimmune disorders","volume":"40","author":"Seifert","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.01.032_bib69","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.kint.2026.01.032_bib70","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1461102","article-title":"CAR immunotherapy in autoimmune diseases: promises and challenges","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib72","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.032_bib73","doi-asserted-by":"crossref","first-page":"4846.1","DOI":"10.1182\/blood-2024-212347","article-title":"A phase 1 study of NKX019, an allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapy in patients with systemic lupus erythematosus","volume":"144","author":"Askanase","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.032_bib74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.kint.2026.01.032_bib75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2018.04.006","article-title":"La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease","volume":"192","author":"Meng","year":"2018","journal-title":"Clin Immunol"},{"issue":"suppl 9","key":"10.1016\/j.kint.2026.01.032_bib76","article-title":"Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells [abstract]","volume":"74","author":"Mog","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.01.032_bib77","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib78","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00262-003-0496-2","article-title":"T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent","volume":"53","author":"Gruen","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.kint.2026.01.032_bib79","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.032_bib80","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib81","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","article-title":"An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.kint.2026.01.032_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.kint.2026.01.032_bib83","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.01.032_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007398","article-title":"CLN-978, a novel half-life extended CD19\/CD3\/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression","volume":"11","author":"Meetze","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.kint.2026.01.032_bib132","unstructured":"A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus. ClinicalTrials.gov Identifier: NCT06613360. Updated November 26, 2026. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06613360"},{"key":"10.1016\/j.kint.2026.01.032_bib85","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib86","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.01.032_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/967584","article-title":"Association of intrarenal B-cell infiltrates with clinical outcome in lupus nephritis: a study of 192 cases","volume":"2012","author":"Shen","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108488","article-title":"B-cell oligoclonal expansions in renal tissue of patients with immune-mediated glomerular disease","volume":"217","author":"Kolovou","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib89","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.032_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823204","article-title":"B-cell dysregulation in idiopathic nephrotic syndrome: what we know and what we need to discover","volume":"13","author":"Colucci","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.imlet.2023.08.001","article-title":"Elevated circulating CD19(+)CD24(hi)CD38(hi) B cells display pro-inflammatory phenotype in idiopathic membranous nephropathy","volume":"261","author":"Deng","year":"2023","journal-title":"Immunol Lett"},{"key":"10.1016\/j.kint.2026.01.032_bib92","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/joneph\/18.3.328","article-title":"CD20-positive infiltrates in human membranous glomerulonephritis","volume":"18","author":"Cohen","year":"2005","journal-title":"J Nephrol"},{"key":"10.1016\/j.kint.2026.01.032_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib94","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.032_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670290","article-title":"The wanderings of gut-derived IgA plasma cells: impact on systemic immune responses","volume":"12","author":"Keppler","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib96","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00281-014-0431-y","article-title":"B cell-mediated pathogenesis of ANCA-mediated vasculitis","volume":"36","author":"Jennette","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.kint.2026.01.032_bib97","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/sj.ki.5000135","article-title":"Natural autoantibodies against glomerular basement membrane exist in normal human sera","volume":"69","author":"Cui","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.032_bib98","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ki.2013.457","article-title":"B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection","volume":"85","author":"Nouel","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.032_bib99","article-title":"Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies","volume":"4","author":"Zhang","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.kint.2026.01.032_bib100","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.kint.2024.02.008","article-title":"CAR T-cell therapy-paving the way for sensitized kidney transplant patients","volume":"105","author":"Jarmi","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.032_bib101","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2021.07.012","article-title":"Kidney transplant T cell-mediated rejection occurring after anti-CD19 CAR T-cell therapy for refractory aggressive burkitt-like lymphoma with 11q aberration: a case report","volume":"79","author":"de Nattes","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.032_bib102","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/SPC.0000000000000699","article-title":"Supportive care measures for bispecific T-cell engager therapies in haematological malignancies","volume":"18","author":"Chen","year":"2024","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.kint.2026.01.032_bib103","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's oncology group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-Cell all in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.032_bib104","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae027","article-title":"Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies","volume":"17","author":"Leon-Roman","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.01.032_bib105","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.kint.2026.01.032_bib106","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.3390\/cells11243991","article-title":"Acute kidney injury in cancer immunotherapy recipients","volume":"11","author":"Joseph","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.kint.2026.01.032_bib107","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/OTT.S465679","article-title":"Nephrotoxicity in bispecific antibodies recipients: focus on T-cell-engaging bispecific antibodies","volume":"17","author":"Wen","year":"2024","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.kint.2026.01.032_bib108","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","article-title":"Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.01.032_bib109","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jtct.2025.03.007","article-title":"Nephrotoxicity in CAR-T cell therapy","volume":"31","author":"Sadowski","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.kint.2026.01.032_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77720-z","article-title":"Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes","volume":"14","author":"Russo","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2026.01.032_bib111","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2026.01.032_bib112","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.xkme.2021.03.011","article-title":"Acute kidney injury following chimeric antigen receptor T-cell therapy for B-cell lymphoma in a kidney transplant recipient","volume":"3","author":"Melilli","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.kint.2026.01.032_bib113","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41581-024-00875-5","article-title":"Lymphocytes and innate immune cells in acute kidney injury and repair","volume":"20","author":"Lee","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.01.032_bib114","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1172\/JCI124614","article-title":"Reparative T lymphocytes in organ injury","volume":"129","author":"D'Alessio","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.01.032_bib115","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1172\/JCI200112080","article-title":"Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure","volume":"108","author":"Burne","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.01.032_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48213-2","article-title":"Single cell and spatial transcriptomics analysis of kidney double negative T lymphocytes in normal and ischemic mouse kidneys","volume":"13","author":"Gharaie","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2026.01.032_bib117","doi-asserted-by":"crossref","first-page":"829.e1","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.kint.2026.01.032_bib118","article-title":"Immunotherapy and the spectrum of kidney disease: should we individualize the treatment?","volume":"9","author":"Bermejo","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2026.01.032_bib119","article-title":"Immunotherapies and renal injury","volume":"31","author":"Shaikh","year":"2022","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.kint.2026.01.032_bib120","article-title":"Nephrotoxicity of targeted therapy used to treat lung cancer","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib121","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.kint.2026.01.032_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1454747","article-title":"Cutting-edge approaches to B-cell depletion in autoimmune diseases","volume":"15","author":"Robinson","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib123","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.kint.2026.01.032_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cei\/uxae031","article-title":"Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?","volume":"217","author":"Shah","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2026.01.032_bib133","unstructured":"CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease (CASTLE). ClinicalTrials.gov Identifier: NCT06347718. Updated September 30, 2025. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06347718"},{"key":"10.1016\/j.kint.2026.01.032_bib134","unstructured":"KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis. ClinicalTrials.gov Identifier: NCT05938725. Updated October 29, 2025. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05938725"},{"key":"10.1016\/j.kint.2026.01.032_bib135","unstructured":"A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1). ClinicalTrials.gov Identifier: NCT05869955. Updated January 13, 2026. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05869955"},{"key":"10.1016\/j.kint.2026.01.032_bib136","unstructured":"MB-CART19.1 in Refractory SLE. ClinicalTrials.gov Identifier: NCT06189157. Updated November 26, 2025. Accessed March 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06189157"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826001456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826001456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:13:00Z","timestamp":1779163980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826001456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0085253826001456"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.01.032","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tiny warriors, big impact: targeted immunotherapy in kidney diseases","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}